Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Executive Summary

Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.


Related Content

Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer
What Late-Breakers To Look Out For At ASCO 2019
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
Lonsurf Hits Phase III OS Target In Gastric Cancer Study
Merck KGaA Highlights Mavenclad Advances In Tough Quarter
FDA Approval Round Up: Keytruda, Opdivo Add Claims
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
FDA's NDA And BLA Approvals: Radicava, Minolira, Bavencio
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts